Sign Up
OverviewAPI
Aptorum Group Limited reported financial results and provided a business update for the six-month period ended June 30, 2023. The company is focused on advancing its therapeutic programs in oncology, autoimmune, and infectious diseases. It completed Pre-IND discussions with the US FDA for ALS-4 and submitted a Phase 1b/2a clinical trial protocol of SACT-1 to US FDA. The company also entered into a non-binding Letter of Intent and Term Sheet to merge its subsidiary with Universal Sequencing Technology Corporation. Additionally, the company raised approximately $1,625,745 in gross proceeds through an ATM program and announced the resignations of key personnel.

Ask a question